FACULTY
Amir Fathi, MD
Associate Professor of Medicine
Harvard Medical School
Program Director, Center for Leukemia
Massachusetts General Hospital
Boston, MA
PROGRAM OVERVIEW
This enduring activity provides healthcare professionals with the latest insights into the treatment of acute myeloid leukemia (AML). Participants will explore cutting-edge molecular and genetic data, learn to optimize treatment strategies for newly diagnosed and relapsed/refractory AML, and gain tools to effectively monitor and manage potential adverse events. Designed to enhance clinical decision-making, this program empowers providers to deliver personalized, evidence-based care for AML patients.
TARGET AUDIENCE
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with AML.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess the latest molecular and genetic data in the treatment of AML
- Justify best practices in managing newly diagnosed and relapsed/refractory AML, considering individual patient and disease-related factors
- Evaluate potential adverse events linked to AML to guarantee efficient monitoring and management.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.75 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Dr. Fathi has received consulting fees from: AstraZeneca, Takeda, Schrodinger, Servier, AbbVie Inc., Bristol Myers Squibb, Prelude, Kura. He has also received research support from – Bristol Myers Squibb, Servier, Kura, AbbVie Inc.
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Michael Page, PharmD, RPh, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
- Naomi De Brito, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (dietary, physical, etc). Please contact Med Learning Group prior to the live event at [email protected]
RELEASED DATE: February 01, 2025
EXPIRATION DATE: February 01, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
